May 9, 2013
Kowa Company announced on May 7 that it submitted on the same day a clinical trial plan notification for the investigational anticancer agent NC-6300 (K-912) to the Pharmaceuticals and Medical Devices Agency (PMDA). NC-6300 (K-912) has been codeveloped by Kowa...read more